MA-ALIRA-HEALTH
16.11.2021 15:03:04 CET | Business Wire | Press release
Alira Health (http://www.alirahealth.com/ ), a global health care consultancy, announced that it has acquired Patchai, a digital health technology company headquartered in Italy. Patchai offers intelligent digital health solutions that engage and empower patients in clinical research and care pathways, enabling better self-management of their health conditions, improving adherence to study protocols and care plans, while facilitating care delivery for clinicians with robust, real-time data. Patchai’s Co-PRO® suite of technologies personalizes patient experience, ensuring high patient satisfaction and retention in decentralized clinical trials. This is Alira Health’s second digital health acquisition, furthering the company’s rapid expansion into patient-centric, technology-enabled solutions for healthcare providers, payers, and suppliers.
“Alira Health is investing heavily in the use of technology to boost patient engagement, improve clinical trials, and collect and apply valuable real-world evidence. We are committed to humanizing health care through innovative, patient-centric technology solutions. Our acquisition of Patchai is a strategic step in realizing our vision of being the market leader in technology used for the collection of patient data in real world studies,” said Gabriele Brambilla, Co-Founder and CEO of Alira Health.
“Patchai’s mission is to advance life sciences with intelligent and human-centered solutions to channel and magnify the positive impact that bio-pharmaceutical companies, healthcare professionals and patients have on the future of health systems," said Alessandro Monterosso, Co-Founder and CEO of Patchai. “We are extremely pleased to join Alira Health and be part of their mission to transform healthcare globally by engaging patients at every step of their journey.”
Patchai has developed an intelligent platform embedding an empathetic virtual companion to deliver personalized human centric interactions to patients and collect Real World Data in real time. Preliminary data on patients using Patchai technology shows a patients’ protocol adherence up to 95%, significantly higher than other digital solutions on the market today and up to nine times higher than paper-based solutions. Patchai was accelerated by Plug and Play Tech Center in Silicon Valley and was finalist at the Catapult Awards, one of the flagship programs of EIT Health. The company, now part of Alira Health, will continue to advance its technologies to offer scalable and modular solutions for Decentralized Clinical Research and Virtual standard care.
About Patchai
Founded in 2018, Patchai’s vision is to make clinical research and routine care more engaging, smart and accessible to improve people’s quality of life. Patchai developed an intelligent platform for patient engagement and real-time data capture in decentralized clinical research and standard care. It enables clinical research and standard clinical practice to become more humane, connected and streamlined. In 2021, Patchai has been included in the Global Top 100 Digital Health Companies by The Medical Futurist Institute.
Learn more at www.patchai.io .
About Alira Health:
Alira Health is an international patient-centric and technology-enabled advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.
Alira Health was founded in 1999 and is based in Framingham, MA, U.S. Alira Health has offices in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Bologna and Verona, Italy; Basel, Switzerland; and Cambridge, UK.
Learn more at www.alirahealth.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom